This new hydrogel version, called Gelzempic (formally AdoGel® Sema), can significantly simplify treatment by increasing the interval between injections from once a week to once a month.
Adocia’s approach addresses a major problem with existing semaglutide drugs: patient retention. Currently, patients must take weekly injections or daily pills, leading to a 60 percent failure rate within a year of starting. Gelzempic’s hydrogel formula, which releases the drug in a controlled manner over a month, aims to improve the situation.
Initial tests on lab mice showed the gel was effective and well tolerated, with no signs of inflammation or additional toxicity. Adocia plans to continue testing Gelzempik in pigs, whose skin and endocrine systems are similar to humans. If successful, human trials could begin within the next few years.
News materials are not equivalent to a doctor’s prescription. Consult a specialist before making a decision.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
